Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;20(1):e1-e4.
doi: 10.1016/j.clcc.2020.07.007. Epub 2020 Jul 30.

Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review

Anthony Stack  1 , Rashmi Khanal  2 , Crystal S Denlinger  3
Affiliations
Review

Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review

Anthony Stack et al. Clin Colorectal Cancer. 2021 Mar.

Abstract

Oxaliplatin-induced immune thrombocytopenia is a rare manifestation of oxaliplatin hypersensitivity, presenting as an acute onset of severe thrombocytopenia after oxaliplatin administration. No standard therapeutic approach outside of permanent discontinuation of oxaliplatin exists. Here, we present a case of oxaliplatin-induced immune thrombocytopenia occurring after oxaliplatin retreatment for metastatic colon cancer. Possible mechanisms of disease and approach to treatment are discussed.

Keywords: Colorectal cancer; Drug reaction; FOLFOX; Gastrointestinal cancers; Hypersensitivity reaction.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Blood counts after oxaliplatin infusion (day 0).
See this image and copyright information in PMC

References

    1. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–3116. doi: 10.1200/JCO.2008.20.6771 - DOI - PubMed
    1. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–2947. doi: 10.1200/JCO.2000.18.16.2938 - DOI - PubMed
    1. Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119(2):438–444. doi: 10.1002/cncr.27732 - DOI - PubMed
    1. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol Off J Eur Soc Med Oncol. 1998;9(1):105–108. - PubMed
    1. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol. 2006;24(3):394–400. doi: 10.1200/JCO.2005.03.0106 - DOI - PubMed

MeSH terms

Supplementary concepts